Anastasiadis Kyriakos, Antonitsis Polychronis, Voucharas Christos, Apostolidou-Kiouti Fani, Deliopoulos Apostolos, Haidich Anna-Bettina, Argiriadou Helena
Cardiothoracic Department, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece.
Department of Hygiene, Social-Preventive Medicine and Medical Statistics, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece.
Eur J Cardiothorac Surg. 2025 Mar 28;67(4). doi: 10.1093/ejcts/ezaf112.
The question whether minimally invasive extracorporeal circulation (MiECC) represents the optimal perfusion strategy in cardiac surgery remains unanswered. We sought to systematically review the entire literature and thoroughly address the impact of MiECC versus conventional cardiopulmonary bypass (cCPB) on adverse clinical outcomes after cardiac surgery.
We searched PubMed, Scopus and Cochrane databases for appropriate articles as well as conference proceedings from major congresses up to 31 August 2024. All randomized controlled trials (RCTs) that fulfilled pre-defined MiECC criteria were included in the analysis. The primary outcome was mortality, while morbidity and transfusion requirements were secondary outcomes. The risk of bias was assessed using the Cochrane Risk of Bias 2 tool. All studies meeting the outcomes of interest of this systematic review were eligible for synthesis.
Of the 738 records identified, 36 RCTs were included in the meta-analysis with a total of 4849 patients. MiECC was associated with significantly reduced mortality [odds ratio (OR) 0.66; 95% confidence interval (CI) 0.53-0.81; P = 0.0002; I2 = 0%] as well as risk of postoperative myocardial infarction (OR 0.42; 95% CI 0.26-0.68; P = 0.002; I2 = 0%) and cerebrovascular events (OR 0.55; 95% CI 0.37-0.80; P = 0.007; I2 = 0%). Moreover, MiECC reduced RBC transfusion requirements, blood loss and rate of re-exploration for bleeding together with incidence of atrial fibrillation. This resulted in significantly reduced duration of mechanical ventilation, ICU and hospital stay.
This meta-analysis provides robust evidence for the beneficial effect of MiECC in reducing postoperative morbidity and mortality after cardiac surgery and prompts for a wider adoption of this technology.
微创体外循环(MiECC)是否是心脏手术的最佳灌注策略这一问题仍未得到解答。我们试图系统地回顾全部文献,并全面探讨MiECC与传统心肺转流(cCPB)相比对心脏手术后不良临床结局的影响。
我们检索了PubMed、Scopus和Cochrane数据库中的相关文章以及截至2024年8月31日各大会议的会议记录。所有符合预定义MiECC标准的随机对照试验(RCT)均纳入分析。主要结局是死亡率,次要结局是发病率和输血需求。使用Cochrane偏倚风险2工具评估偏倚风险。所有符合本系统评价感兴趣结局的研究均符合综合分析条件。
在检索到的738条记录中,36项RCT纳入荟萃分析,共4849例患者。MiECC与死亡率显著降低相关[比值比(OR)0.66;95%置信区间(CI)0.53 - 0.81;P = 0.0002;I² = 0%],以及术后心肌梗死风险(OR 0.42;95% CI 0.26 - 0.68;P = 0.002;I² = 0%)和脑血管事件风险(OR 0.55;95% CI 0.37 - 0.80;P = 0.007;I² = 0%)。此外,MiECC减少了红细胞输血需求、失血量和再次开胸止血率以及房颤发生率。这导致机械通气时间、重症监护病房(ICU)住院时间和住院总时间显著缩短。
这项荟萃分析为MiECC在降低心脏手术后发病率和死亡率方面的有益作用提供了有力证据,并促使该技术得到更广泛的应用。